Genetically engineered NSCs programmed to produce therapeutic cocktail comprising IL-10, NT-3, and LINGO-1-Fc mediated recovery through inducing M2 macrophages/microglia, reducing astrogliosis, and promoting axonal integrity and endogenous oligodendrocyte/neuron differentiation, thereby demonstrating a new and potentially efficient therapy against the chronic stage of MS [296]. The gene discussed is IL10; the disease is myeloid sarcoma.